arrow
B

Bianca F. Goemans

princess maxima center for pediatric oncology
H指数:20
被引数:1,528

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML

通过隧道纳米管介导的线粒体转移驱动儿童急性髓系白血病中巨噬细胞的免疫抑制和代谢重编程

Leukemia
IF13.4
2026-10-090
OAAI
CPX-351 in Down Syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase III ML-DS 2018 Trial

CPX-351在Down Syndrome-associated Myeloid Leukemia中的研究结果及预后因素:来自III期ML-DS 2018试验的数据

Blood
IF23.1
2025-10-240
OAAI
Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

儿童急性髓系白血病(AML)的诊断与管理:国际专家小组的共识建议

Blood
IF23.1
2025-10-220
PRE
Bone marrow lymphocyte dynamics during chemotherapy in pediatric acute myeloid leukemia

化疗期间儿童急性髓系白血病患者骨髓淋巴细胞动力学

2025-09-120
PREAI
Implementation of paediatric precision oncology into clinical practice: The individualized therapies for children with cancer program 'iTHER' (vol 175, pg 311, 2022)

将儿科精准肿瘤学纳入临床实践:儿童癌症个体化治疗计划'iTHER'(卷175,页311,2022年)

2025-05-010
OAAI
Somatic genetic development of Wilms tumor via normal kidneys in predisposed children

易感儿童通过正常肾脏进行Wilms肿瘤的体细胞遗传发育

2024-09-050
PRE
Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms

铂化合物的选择性压力影响了与治疗相关的髓系肿瘤的发展

2024-07-171
OAAI
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
2023-10-278
OAAI
Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
2023-02-2330
OAAI
Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'

儿科精准肿瘤学在临床实践中的实施: 儿童癌症的个性化治疗方案 “ither”

2022-11-0129
OAAI
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

复发或难治性急性淋巴细胞白血病患儿接受inotuzumab ozogamicin治疗后嵌合抗原受体T细胞治疗的结果

LEUKEMIA
IF13.4
2022-10-309
PRE
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS

代表i-bfm AML研究组和ewog-mds的非唐氏综合征新生儿骨髓增生性疾病管理指南

2021-12-026
OAAI
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

儿科精确肿瘤学信息注册中心: 具有非常高证据目标的患者的临床结果和益处

2021-08-09128
OAAI
Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia

敏感的GATA1突变筛查可可靠地识别患有唐氏综合征的新生儿,其具有髓系白血病的风险

LEUKEMIA
IF13.4
2021-01-2211
OAAI